
Sanofi is the first and only company in the world to receive an approval for a drug targeting the disease acid sphingomyelinase deficiency (ASMD), Sanofi reports in a press release.
This also makes Japan the first country in the world to approve a drug in this indication, as it was the Japanese health authority that granted Sanofi the approval for Xenpozyme (olipudase alfa) as a treatment for adults and children with non-central nervous system manifestations of ASMD.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app